Dılşa Mızrak Kaya
Dılşa Mızrak Kaya publishes mostly in Pulmonary and Respiratory Medicine, Surgery and Oncology, on topics such as Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment and Gastrointestinal Tumor Research and Treatment.
- World rank
- #7,358,224 of 7,710,434 ranked researchers
- Rank in United States
- #1,603,287 of 1,627,098
- Works
- 58
- Citations
- 366
- Citations per work
- 6.3
What does Dılşa Mızrak Kaya research?
Dılşa Mızrak Kaya's work is mostly in Medicine (77%), Biochemistry, Genetics and Molecular Biology (4%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences4577.2%
- Medicine4577.2%
- Everything else1118.7%
- Life Sciences24.1%
- 1Pulmonary and Respiratory Medicine24% of their works
- 2Surgery23% of their works
- 3Oncology20% of their works
- 4Gastroenterology6% of their works
- 5Pathology and Forensic Medicine5% of their works
- 6Cancer Research4% of their works
Research topics
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Gastrointestinal Tumor Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Inflammatory Biomarkers in Disease Prognosis
Which keywords describe Dılşa Mızrak Kaya's research?
The keywords of their largest research topics: Endoscopic Resection, Chemotherapy, Neoadjuvant Therapy, Gastric Cancer, Molecular Characterization, Esophageal Carcinoma, Preoperative Chemoradiotherapy and Tumor Microenvironment.
- Inflammation
- Targeted Therapy
- EGFR Mutations
- PD-1 and PD-L1
- Surgical Complications
- Sunitinib
- Tumor Microenvironment
- Esophageal Carcinoma
- Gastric Cancer
- Chemotherapy
- Endoscopic Resection
- Neoadjuvant Therapy
- Molecular Characterization
- Preoperative Chemoradiotherapy
- Imatinib Mesylate
- Pancreatic Cancer
- Immune Checkpoint Blockade
- Cetuximab
- KRAS Mutations
- Cancer
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.
All 20 words, with their numbers
- Endoscopic Resection562 topics
- Chemotherapy423 topics
- Neoadjuvant Therapy332 topics
- Gastric Cancer301 topic
- Molecular Characterization301 topic
- Esophageal Carcinoma261 topic
- Preoperative Chemoradiotherapy261 topic
- Tumor Microenvironment173 topics
- Imatinib Mesylate101 topic
- Sunitinib101 topic
- Pancreatic Cancer71 topic
- Surgical Complications71 topic
- Immune Checkpoint Blockade61 topic
- PD-1 and PD-L161 topic
- Cetuximab51 topic
- EGFR Mutations51 topic
- KRAS Mutations51 topic
- Targeted Therapy51 topic
- Cancer41 topic
- Inflammation41 topic
Where does Dılşa Mızrak Kaya work?
Dılşa Mızrak Kaya's main affiliation in the publication record is The University of Texas MD Anderson Cancer Center, United States.
How many publications and citations does Dılşa Mızrak Kaya have?
OpenAlex counts 58 works and 366 citations for Dılşa Mızrak Kaya, an h-index of 11, ranking #7,358,224 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Dılşa Mızrak Kaya. Posts are plain text and can be reported.